AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23673865 — intervention group
Group type: COMPARATOR
Intervention: Saline administration (Control)
Number of subjects: 26
Study 21103330 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical mask worn by index case for 5 days
Number of subjects: 105
Study 21103330 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mask)
Number of subjects: 105
Study 18420499 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel
Number of subjects: 4950
Study 18420499 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel every 3 weeks
Number of subjects: 4950
Study 18420499 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly docetaxel
Number of subjects: 4950
Study 18420499 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel every 3 weeks (standard therapy)
Number of subjects: 4950
Study 16046046 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone implants
Number of subjects: 0
Study 16046046 — intervention group
Group type: COMPARATOR
Intervention: Levomethadone
Number of subjects: 0
Study 16046046 — intervention group
Group type: COMPARATOR
Intervention: Actively consuming opiate addicts
Number of subjects: 0
Study 16046046 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 12838059 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal-on-metal prostheses
Number of subjects: 59
Study 12838059 — intervention group
Group type: COMPARATOR
Intervention: Ceramic-on-polyethylene prostheses
Number of subjects: 59
Study 12838059 — intervention group
Group type: EXPERIMENTAL
Intervention: Both types of prostheses
Number of subjects: 59
Study 11778513 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sustained release theophylline (Protheo) (200 mg/night) and inhaled BDP (300 micrograms/day)
Number of subjects: 43
Study 11778513 — intervention group
Group type: COMPARATOR
Intervention: Inhaled BDP (600 micrograms/day) and oral placebo
Number of subjects: 43
Study 9275365 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human granulocyte colony-stimulating factor (rhG‐CSF)
Number of subjects: 120
Study 9275365 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 120
Study 1311008 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (NS)
Number of subjects: 16
Study 1311008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 6643191 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise test
Number of subjects: 12
Study 6643191 — intervention group
Group type: COMPARATOR
Intervention: Cycle ergometer exercise test
Number of subjects: 12
Study 6643191 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental exercise tests with various work rate increments
Number of subjects: 12
Study 6643191 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental exercise tests
Number of subjects: 12
Study 30110719 — intervention group
Group type: COMPARATOR
Intervention: 5 mg Co2+ single oral dosage
Number of subjects: 18
Study 30110719 — intervention group
Group type: COMPARATOR
Intervention: 10 mg Co2+ single oral dosage
Number of subjects: 18
Study 30110719 — intervention group
Group type: COMPARATOR
Intervention: 5 mg Co2+ daily dosage for five days
Number of subjects: 18
Study 30110719 — intervention group
Group type: COMPARATOR
Intervention: 10 mg Co2+ daily dosage for five days
Number of subjects: 18
Study 30207920 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod (0.5 mg per day; 0.25 mg per day for patients with body weight ≤40 kg)
Number of subjects: 215
Study 30207920 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta‐1a (30 μg per week)
Number of subjects: 215
Study 30207920 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod
Number of subjects: 215
Study 30207920 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta‐1a
Number of subjects: 215
Study 27456005 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mL flush every 24 hours
Number of subjects: 160
Study 27456005 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mL flush every 6 hours
Number of subjects: 160
Study 27456005 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL flush every 24 hours
Number of subjects: 160
Study 27456005 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL flush every 6 hours
Number of subjects: 160
Study 27456005 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 160
Study 24401930 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2 and fluorouracil 1000 mg/m2 (120-h infusion every 21 days) for three cycles
Number of subjects: 198
Study 24401930 — intervention group
Group type: COMPARATOR
Intervention: Control group received upfront surgery
Number of subjects: 198
Study 24401930 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and fluorouracil chemotherapy
Number of subjects: 198
Study 22363366 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice containing sodium monofluorophosphate (1000 ppm) and calcium glycerophosphate
Number of subjects: 595
Study 22363366 — intervention group
Group type: COMPARATOR
Intervention: Non-fluoridated dentifrice (placebo)
Number of subjects: 595
Study 21302724 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve repair
Number of subjects: 80
Study 21302724 — intervention group
Group type: COMPARATOR
Intervention: Mitral valve replacement
Number of subjects: 80
Study 17617202 — intervention group
Group type: EXPERIMENTAL
Intervention: AFP (cutoff of 20 ng/mL)
Number of subjects: 372
Study 17617202 — intervention group
Group type: EXPERIMENTAL
Intervention: AFP (cutoff of 200 ng/mL)
Number of subjects: 372
Study 17617202 — intervention group
Group type: EXPERIMENTAL
Intervention: AFP-L3% (cutoff of 10%)
Number of subjects: 372
Study 17617202 — intervention group
Group type: EXPERIMENTAL
Intervention: AFP-L3% (in patients with elevated AFP 20-200 ng/mL)
Number of subjects: 372
Study 17617202 — intervention group
Group type: COMPARATOR
Intervention: AFP-L3% vs AFP
Number of subjects: 372
Study 15882523 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol vaccination with HPV16L1 VLPs
Number of subjects: 0
Study 15882523 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular vaccination with HPV16 VLPs
Number of subjects: 0
Study 12414850 — intervention group
Group type: EXPERIMENTAL
Intervention: ERT/HRT
Number of subjects: 489
Study 12414850 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ERT/HRT and calcitriol
Number of subjects: 489
Study 12414850 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol
Number of subjects: 489
Study 12414850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 489
Study 10220494 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5, 10, or 20 mg/kg)
Number of subjects: 30
Study 10220494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10220494 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 30
Study 8557883 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone treatment
Number of subjects: 8
Study 8557883 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 8
Study 8557883 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall analysis
Number of subjects: 8
Study 2365894 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy ratings
Number of subjects: 36
Study 2365894 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy ratings and previous smoking behavior
Number of subjects: 36
Study 508506 — intervention group
Group type: EXPERIMENTAL
Intervention: Triprolidine hydrochloride (2.5 mg)
Number of subjects: 6
Study 508506 — intervention group
Group type: EXPERIMENTAL
Intervention: Triprolidine hydrochloride (10 mg, sustained release)
Number of subjects: 6
Study 508506 — intervention group
Group type: EXPERIMENTAL
Intervention: Brompheniramine maleate (4 mg)
Number of subjects: 6
Study 508506 — intervention group
Group type: EXPERIMENTAL
Intervention: Brompheniramine maleate (12 mg, sustained release)
Number of subjects: 6
Study 508506 — intervention group
Group type: COMPARATOR
Intervention: Subjective assessments of performance, well-being, and sleep
Number of subjects: 6
Study 31756640 — intervention group
Group type: EXPERIMENTAL
Intervention: Deglycosylated IgM
Number of subjects: 59
Study 31756640 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-deglycosylated IgM
Number of subjects: 59
Study 31756640 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 59
Study 31553944 — intervention group
Group type: EXPERIMENTAL
Intervention: Quiet Eye Training (QET)
Number of subjects: 30
Study 31553944 — intervention group
Group type: EXPERIMENTAL
Intervention: Quiet Mind Training (QMT)
Number of subjects: 30
Study 31553944 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 30
Study 28818742 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV DNA testing with liquid-based cytology (n=9257)
Number of subjects: 18402
Study 28818742 — intervention group
Group type: COMPARATOR
Intervention: Liquid-based cytology (control group, n=9145)
Number of subjects: 18402
Study 25896873 — intervention group
Group type: EXPERIMENTAL
Intervention: I‐MUR service provided by trained pharmacists immediately after baseline Asthma Control Test (ACT) score
Number of subjects: 1800
Study 25896873 — intervention group
Group type: COMPARATOR
Intervention: I‐MUR service provided by trained pharmacists three months after baseline ACT score
Number of subjects: 1800
Study 25896873 — intervention group
Group type: EXPERIMENTAL
Intervention: I‐MUR service
Number of subjects: 1800
Study 23450056 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG)
Number of subjects: 0
Study 23450056 — intervention group
Group type: COMPARATOR
Intervention: Metformin (MET)
Number of subjects: 0
Study 21078545 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (60 and 120 mg/day)
Number of subjects: 48
Study 21078545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 20030854 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrectomy with metastasectomy plus systemic chemotherapy (GYMS)
Number of subjects: 0
Study 20030854 — intervention group
Group type: COMPARATOR
Intervention: Systemic chemotherapy alone (SA)
Number of subjects: 0
Study 18823466 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alpha activated (DrotAA) treatment
Number of subjects: 46
Study 18823466 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment for sepsis without DrotAA
Number of subjects: 46
Study 15878495 — intervention group
Group type: EXPERIMENTAL
Intervention: Qvar Autohaler 800 microg/day
Number of subjects: 460
Study 15878495 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone Diskus 1000 microg/day
Number of subjects: 460
Study 15878495 — intervention group
Group type: COMPARATOR
Intervention: Budesonide Turbuhaler 1600 microg/day
Number of subjects: 460
Study 12077033 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg administered orally once daily
Number of subjects: 150
Study 12077033 — intervention group
Group type: COMPARATOR
Intervention: Indometacin 50 mg administered orally three times daily
Number of subjects: 150
Study 9862081 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin
Number of subjects: 12
Study 9862081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7608801 — intervention group
Group type: COMPARATOR
Intervention: Heparin CVC flush solution
Number of subjects: 63
Study 7608801 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-vancomycin CVC flush solution
Number of subjects: 63
Study 2476767 — intervention group
Group type: EXPERIMENTAL
Intervention: S80 lead
Number of subjects: 99
Study 2476767 — intervention group
Group type: EXPERIMENTAL
Intervention: 423S lead
Number of subjects: 99
Study 2476767 — intervention group
Group type: EXPERIMENTAL
Intervention: S100 lead
Number of subjects: 99
Study 2476767 — intervention group
Group type: COMPARATOR
Intervention: All leads
Number of subjects: 99
Study 1067402 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (Gly‐Oxide Liquid)
Number of subjects: 69
Study 1067402 — intervention group
Group type: COMPARATOR
Intervention: Control (group I)
Number of subjects: 69
Study 1067402 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group II)
Number of subjects: 69
Study 29152875 — intervention group
Group type: EXPERIMENTAL
Intervention: Teach-back method
Number of subjects: 263
Study 29152875 — intervention group
Group type: COMPARATOR
Intervention: Traditional methods (Control)
Number of subjects: 263
Study 29141357 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant and vasodilator drugs (preventive group)
Number of subjects: 58
Study 29141357 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant and vasodilator drugs (treatment group)
Number of subjects: 58
Study 29141357 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 58
Study 26314662 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated protocol (18 mW/cm(2), 5 min)
Number of subjects: 31
Study 26314662 — intervention group
Group type: COMPARATOR
Intervention: Standard method (3 mW/cm(2), 30 min)
Number of subjects: 31
Study 26314662 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both methods
Number of subjects: 31
Study 23475029 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine (0.4 mg/kg) as a bolus followed by propofol
Number of subjects: 32
Study 23475029 — intervention group
Group type: COMPARATOR
Intervention: Saline followed by propofol (treatment-as-usual group)
Number of subjects: 32
Study 21561501 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine
Number of subjects: 275
Study 21561501 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine spray
Number of subjects: 275
Study 21561501 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 275
Study 21561501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275
Study 18296564 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (inhibits prostaglandin production)
Number of subjects: 24
Study 18296564 — intervention group
Group type: COMPARATOR
Intervention: Saline control (for indomethacin)
Number of subjects: 24
Study 18296564 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (inhibits adenosine receptors)
Number of subjects: 24
Study 18296564 — intervention group
Group type: COMPARATOR
Intervention: Saline control (for aminophylline)
Number of subjects: 24
Study 16482199 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 20 mg
Number of subjects: 165
Study 16482199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 14511041 — intervention group
Group type: EXPERIMENTAL
Intervention: Benign prostatic hyperplasia (BPH)
Number of subjects: 20
Study 14511041 — intervention group
Group type: COMPARATOR
Intervention: Control (normal prostate tissue)
Number of subjects: 20
Study 14511041 — intervention group
Group type: EXPERIMENTAL
Intervention: BPH
Number of subjects: 20
Study 10696962 — intervention group
Group type: EXPERIMENTAL
Intervention: Retropubic urethrocystopexy (sutures and fibrin sealant)
Number of subjects: 45
Study 10696962 — intervention group
Group type: EXPERIMENTAL
Intervention: Pubococcygeal repair
Number of subjects: 45
Study 8865916 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil (600 mg/b.i.d.) for three months
Number of subjects: 22
Study 8865916 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin (10 mg/day) for three months
Number of subjects: 22
Study 8865916 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 22
Study 1523321 — intervention group
Group type: EXPERIMENTAL
Intervention: Franseen needle
Number of subjects: 133
Study 1523321 — intervention group
Group type: EXPERIMENTAL
Intervention: Westcott needle
Number of subjects: 133
Study 1523321 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal needle
Number of subjects: 133
Study 1523321 — intervention group
Group type: COMPARATOR
Intervention: Cut biopsy needle
Number of subjects: 133
Study 6581063 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol inhalation powder (50 + 50 + 100 + 200 micrograms)
Number of subjects: 9
Study 6581063 — intervention group
Group type: COMPARATOR
Intervention: Fenoterol inhalation powder (200 + 50 + 50 + 50 micrograms)
Number of subjects: 9
Study 31781666 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3 supplementation (50,000 IUs weekly)
Number of subjects: 30
Study 31781666 — intervention group
Group type: COMPARATOR
Intervention: Low-dose comparator (5,000 IUs weekly)
Number of subjects: 30
Study 31781666 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (high-dose and low-dose)
Number of subjects: 30
Study 29735855 — intervention group
Group type: EXPERIMENTAL
Intervention: Active self-ligating brackets (Nexus, Ormco) with Damon arch form Cu-NiTi and SS wires
Number of subjects: 50
Study 29735855 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive self-ligating bracket system (Empower) with standard Cu-NiTi and SS wires
Number of subjects: 50
Study 29735855 — intervention group
Group type: COMPARATOR
Intervention: Roth prescribed conventional brackets (control group) with standard Cu-NiTi and SS wires
Number of subjects: 50
Study 27565034 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management (TTM) at 33°C for 24h
Number of subjects: 939
Study 27565034 — intervention group
Group type: COMPARATOR
Intervention: Targeted temperature management (TTM) at 36°C for 24h
Number of subjects: 939
Study 27565034 — intervention group
Group type: EXPERIMENTAL
Intervention: Actively cooled or passively rewarmed during the first 4h
Number of subjects: 939
Study 27565034 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature related variables (TTM-groups)
Number of subjects: 939
Study 24439960 — intervention group
Group type: EXPERIMENTAL
Intervention: iTBS 5
Number of subjects: 0
Study 24439960 — intervention group
Group type: EXPERIMENTAL
Intervention: iTBS I
Number of subjects: 0
Study 24439960 — intervention group
Group type: EXPERIMENTAL
Intervention: cTBS 5
Number of subjects: 0
Study 24439960 — intervention group
Group type: EXPERIMENTAL
Intervention: cTBS I
Number of subjects: 0
Study 24439960 — intervention group
Group type: COMPARATOR
Intervention: Sham TBS
Number of subjects: 0
Study 22014532 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention (16 sessions of individual cognitive behavior therapy and combination nicotine replacement therapy for 26 weeks)
Number of subjects: 162
Study 22014532 — intervention group
Group type: COMPARATOR
Intervention: Usual care (referral to a free-standing smoking cessation program with varying duration counseling and medications)
Number of subjects: 162
Study 22014532 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention
Number of subjects: 162
Study 22014532 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 162
Study 20697948 — intervention group
Group type: EXPERIMENTAL
Intervention: Total glucosides of paeony capsule (TGPC) combined with citirizine (10 mg/day)
Number of subjects: 120
Study 20697948 — intervention group
Group type: COMPARATOR
Intervention: Control group (citirizine 10 mg/day)
Number of subjects: 120
Study 18606250 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-run, telephone-based intervention
Number of subjects: 762
Study 18606250 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 762
Study 16149675 — intervention group
Group type: COMPARATOR
Intervention: Midline transperitoneal approach (TPA)
Number of subjects: 36
Study 16149675 — intervention group
Group type: EXPERIMENTAL
Intervention: Left retroperitoneal approach (RPA)
Number of subjects: 36
Study 16149675 — intervention group
Group type: COMPARATOR
Intervention: Both approaches
Number of subjects: 36
Study 11886178 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated-interferon alpha-2b monotherapy (PMT)
Number of subjects: 56
Study 11886178 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with ribavirin (PCT1-low dose ribavirin and PCT2-high dose ribavirin)
Number of subjects: 56
Study 11886178 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT2 (high dose ribavirin)
Number of subjects: 56
Study 11886178 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 56
Study 10452749 — intervention group
Group type: EXPERIMENTAL
Intervention: MSG 2.5 g oral challenge
Number of subjects: 100
Study 10452749 — intervention group
Group type: COMPARATOR
Intervention: Placebo challenge
Number of subjects: 100
Study 10452749 — intervention group
Group type: EXPERIMENTAL
Intervention: MSG sensitivity in individuals with aspirin-sensitive asthma (negative history)
Number of subjects: 100
Study 10452749 — intervention group
Group type: EXPERIMENTAL
Intervention: MSG sensitivity in individuals with MSG-positive history
Number of subjects: 100
Study 7538170 — intervention group
Group type: EXPERIMENTAL
Intervention: r-hGH (0.2 IU/kg.d subcutaneously once a day for seven days, starting on the second day after injury)
Number of subjects: 14
Study 7538170 — intervention group
Group type: EXPERIMENTAL
Intervention: r-hGH
Number of subjects: 14
Study 2288743 — intervention group
Group type: EXPERIMENTAL
Intervention: Low systemic heparinization (ACT > 180 s)
Number of subjects: 12
Study 2288743 — intervention group
Group type: COMPARATOR
Intervention: Full systemic heparinization (ACT > 480 s)
Number of subjects: 12
Study 2288743 — intervention group
Group type: EXPERIMENTAL
Intervention: Low systemic heparinization
Number of subjects: 12
Study 2288743 — intervention group
Group type: COMPARATOR
Intervention: Full systemic heparinization
Number of subjects: 12
Study 7256979 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 0
Study 7256979 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 0
Study 30775267 — intervention group
Group type: EXPERIMENTAL
Intervention: We Can with clinician messaging support (We Can-Ind)
Number of subjects: 303
Study 30775267 — intervention group
Group type: EXPERIMENTAL
Intervention: We Can with moderated carer chatroom support (We Can-Chat)
Number of subjects: 303
Study 30775267 — intervention group
Group type: EXPERIMENTAL
Intervention: We Can with online forum only (We Can-Forum)
Number of subjects: 303
Study 30775267 — intervention group
Group type: EXPERIMENTAL
Intervention: We Can (all conditions)
Number of subjects: 303
Study 29907964 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional injection of bleomycin (1 mg/ml) every 2 weeks for a maximum of four sessions
Number of subjects: 0